Neurogene price target lowered to $38 from $46 at Baird

Baird analyst Joel Beatty lowered the firm’s price target on Neurogene (NGNE) to $38 from $46 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results which showed ita registrational trial design update is on track for the first half of 2025.